C07H 13/12
Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or
Official title: by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
C07H13/12 (Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or) appears on 171 US grants and 142 published applications in this corpus.
Search patents in C07H- Granted patents
- 171
- Published applications
- 142
- Assignees
- 134
- Inventors
- 496
- Latest grant
- 13 May 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 2 | 0 |
| 1977 | 3 | 0 |
| 1978 | 6 | 0 |
| 1979 | 3 | 0 |
| 1980 | 9 | 0 |
| 1981 | 5 | 0 |
| 1982 | 3 | 0 |
| 1983 | 3 | 0 |
| 1984 | 4 | 0 |
| 1985 | 0 | 0 |
| 1986 | 3 | 0 |
| 1987 | 5 | 0 |
| 1988 | 1 | 0 |
| 1989 | 3 | 0 |
| 1990 | 3 | 0 |
| 1991 | 2 | 0 |
| 1992 | 2 | 0 |
| 1993 | 4 | 0 |
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 3 | 0 |
| 1997 | 2 | 0 |
| 1998 | 2 | 0 |
| 1999 | 4 | 0 |
| 2000 | 1 | 0 |
| 2001 | 2 | 0 |
| 2002 | 1 | 1 |
| 2003 | 2 | 5 |
| 2004 | 2 | 3 |
| 2005 | 2 | 1 |
| 2006 | 1 | 1 |
| 2007 | 1 | 5 |
| 2008 | 0 | 3 |
| 2009 | 1 | 2 |
| 2010 | 3 | 6 |
| 2011 | 2 | 6 |
| 2012 | 7 | 11 |
| 2013 | 4 | 3 |
| 2014 | 9 | 16 |
| 2015 | 9 | 9 |
| 2016 | 5 | 15 |
| 2017 | 11 | 8 |
| 2018 | 4 | 11 |
| 2019 | 9 | 4 |
| 2020 | 6 | 4 |
| 2021 | 4 | 7 |
| 2022 | 1 | 3 |
| 2023 | 4 | 5 |
| 2024 | 4 | 11 |
| 2025 | 2 | 2 |
By publication year. Applications have been published since 2001.
Recent patents
- CD206 targeted drug delivery vehicles carrying novel bisphosphonate drug payloads via a degradable linker13 May 2025US 12,297,222 B2Navidea Biopharmaceuticals, Inc.
- Charged surface reversed phase chromatographic materials method for analysis of glycans modified with amphipathic, strongly basic moieties18 Mar 2025US 12,252,557 B2Waters Technologies Corporation
- Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease19 Nov 2024US 12,145,959 B2Shire Human Genetic Therapies, Inc.
- Cell labeling agent and cell labeling kit30 Jul 2024US 12,050,220 B2University of Miyazaki
- CD206 targeted drug delivery vehicles carrying novel bisphosphonate drug payloads via a degradable linker11 Jun 2024US 12,006,339 B2Navidea Biopharmaceuticals, Inc.
- Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease11 Sep 2025US 2025/0282808 A1Shire Human Genetic Therapies, Inc.
- Charged surface reversed phase chromatographic materials method for analysis of glycans modified with amphipathic, strongly basic moieties10 Jul 2025US 2025/0223382 A1Waters Technologies Corporation
- Ribose cationic lipids14 Nov 2024US 2024/0374521 A1Translate Bio, Inc.
- Deuterated nucleoside compounds and use thereof3 Oct 2024US 2024/0327446 A1Medshine Discovery Inc.
- Prodrugs with 1-(disulfanyl)alkyloxy-carbonyl units12 Sep 2024US 2024/0299554 A1PharmaCytics B.V.
Most cited
By later US patents
- Thiocarbon-protecting groups for RNA synthesis121US 8,202,983 B2Agilent Technologies, Inc. · 2012
- Process for the cycloaddition of a halogenated 1,3-dipole compound with a (hetero)cycloalkyne65US 10,266,502 B2Synaffix B.V. · 2019
- 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides60US 5,521,294 AEli Lilly and Company · 1996
- Liposomes useful for drug delivery60US 8,147,867 B2Hermes Biosciences, Inc. · 2012
- Novel pharmaceutically active N-(2-aminoacylamido-2-deoxy-hexosyl)-amides, -carbamates and -ureas51US 4,855,283 ABayer Aktiengesellschaft · 1989